AI aids scientists in designing next-generation medicines

AI for PMs

Investing in robust data collection and AI model training is essential for PMs in drug development to stay competitive and innovate effectively. Ignoring this could lead to slower product cycles and missed opportunities in addressing complex medical challenges.

From the original

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are o…